{"name":"Kymab Limited","slug":"kymab-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxPVnZGYTBfR3o4czAtRFJXU1dwX190aXBvd3dCVUhxUnZXekRSeDR1TmN4ZkpHZWhVSlVBcWNVNXlXYmVQamUzWm9UR0hfY0pkaDNzV0NPdGV1aXFDREEzTGZTOUk0aEppbk9GUGs5b3R6MGdOOHR4djRLTkh2OW1Ub2t0dGh6SUV5VEctOFpOTzRHb05OSmRSVUQzRjhOOEZpZ3hfQ1hONzk0dm9xeEZqeTczSFBoWjllakRONGEzRzI1RDAxMlF6NmM3b0JYajJBWG1oU3dPczFZTkt6a3ZFeU5ER1pkZ0t6S21KVnUzVjhfRV9qRGJNb01HNkVUSVNIV0pmdEU4YU9fcGJBWmU0?oc=5","date":"2026-02-16","type":"pipeline","source":"prnewswire.com","summary":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight - prnewswire.com","headline":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQTExJbEJtdThWcXZ6ZC1QcFdPMV92b1A4ZVdsWnFVRmlucUZiRzBuMGdxVHZFakNTT1BCT0MtcmFxb2JrSlpmRmVhQ24zcG9Xamo1bGxiTDZaWFNnNDJ4eTBLbm5kcmh1RDltRllzVk85YnNYMzU4NXlqWHlSUDk5WEU2RG5LaXZZdWxTT2MxOFBlYnlBdm84U0xXMzFodzVVU29ONndUZkcwTXBfYnBlN1ZObGdwUl9pRWQyOUR3Z0xIQmxRT3VZSG9icTd2bllNUlFZZFZ6VDhhRFd5NnhlVWFWRFp1WllFeWgzenhB?oc=5","date":"2026-01-23","type":"pipeline","source":"Citeline News & Insights","summary":"Sanofi Upbeat About Amlitelimab Despite More Mixed Results - Citeline News & Insights","headline":"Sanofi Upbeat About Amlitelimab Despite More Mixed Results - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFA4SjJKU3NFSUYxanNoSHA3SC1lOW56OXBvVG5Sa3Z4b2lPb2dxVG04NzBERmtKZzRScTJNT1pVbDdkLVhTbXluMWZZQ2NGbzN5aFV6VlV5bVp5dlJkZVpidzQ5ZVFzOS14?oc=5","date":"2025-12-16","type":"pipeline","source":"Wiley Online Library","summary":"Journal of the European Academy of Dermatology and Venereology - Wiley Online Library","headline":"Journal of the European Academy of Dermatology and Venereology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE02Z1FYSzBaS2FZSGc2MC1EZ1pHNVN5MVhlMm9lM0NSTWZzN2RnTVdsdjJyRElCM2hvTllocmlMUjdKVmlpaHJESFgyT3g4eU1iVTZmN0tNQU5WTmJTMEpBOQ?oc=5","date":"2024-06-25","type":"pipeline","source":"The Pharma Letter","summary":"Kymab - The Pharma Letter","headline":"Kymab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOdzZRRGswLXluQ2FwTXhrdGVEVHhFSWdXMTAxWldEdWdEUFV1cURCRkFvb3J6SGFXVWxVQUd4bDg4a1JUb0FpWVhUSlg5TkhFdXltNlVJN1lGMjM4M1NWelVyX29aTV9RQU51UW10c3ZiRzRHUU4zaElTd1Z0S1pJeVl3S1pRY05lNkdRd3RLcm9vbnNvYXV0QnoxVnFGcFdiZktFYlV3MW1oeE0?oc=5","date":"2024-03-11","type":"pipeline","source":"Business Weekly","summary":"Jobs at risk as Sanofi confirms closure of Kymab’s Cambridge facility - Business Weekly","headline":"Jobs at risk as Sanofi confirms closure of Kymab’s Cambridge facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOQUNqdVFEUUE1ck40cWdocjQ1UGV4Ml9lM19lLUpqWWRzVHpoelpmWWI2U2UzY196cWxVc0RMelpwM0YtRjVWbHpTX2xYM2lvVlFteUdVTk0zNEJPV3lELWU4YUtDOGp6eWpCcXMxRVdYTTRacjJkU19QbVptdVJ4aG9adzN1NG5yLU94b3NjUnc3dWVhZVFkeGlDanAxZ1RiMVhJ?oc=5","date":"2024-01-17","type":"pipeline","source":"Healio","summary":"Insect venom causes most occupational anaphylaxis - Healio","headline":"Insect venom causes most occupational anaphylaxis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5SMHFibGtISl9HNThIU2R6aXJJTUlmNXNwOWJiU21odE85RFRHb1BXQWdaRXIxS1plbkFSQlFtSGtBbE9iUzBGOE0xRWdlZVNuc3hYRnJudVdUQ0RXYmVTeWl5Q1FiVWpm?oc=5","date":"2024-01-12","type":"trial","source":"sangerinstitute.blog","summary":"Kymab: CASE STUDY - sangerinstitute.blog","headline":"Kymab: CASE STUDY","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE5qc0tYS3RxUG9VblF2NWxKMmlXNHJFM0xJcEdmSDFjcTY1NHBkdXlDUHR5MmhHNFNTUW15MHRFazhTOG1KcVZyb0Nybi1fSHIyZGl2Vm95NTZ5VUx3WGhwNWhYS2lqVDNsemc?oc=5","date":"2022-06-29","type":"pipeline","source":"Wiley Online Library","summary":"Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances - Wiley Online Library","headline":"Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNTHNxS1VFcXExLUJ4aS13cElwQ3BTSlotSEQ1SFVMb0JqQUVYWHdvVE5TNkpyN0pqZ0RQR3N6cjY5aVBjVXJGZHhkYWsyQVZIakxINGtwLUc2aTBtbG05TElndGp0RF9sWVNNS1NSand1Z2NzZ18xZHJJdl93a3JfX0dKSzVWQ1JPckJBQ2ZZZXk2OE9JcHJtOU9GZw?oc=5","date":"2021-01-11","type":"deal","source":"pharmaphorum","summary":"Sanofi buys UK's Kymab and inflammatory disease hopeful for $1.45bn - pharmaphorum","headline":"Sanofi buys UK's Kymab and inflammatory disease hopeful for $1.45bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQaGJ5czN2RmdaRzNvZFkzUXdUemNmXzkzMm9zZUlvN2MyT19pMzZIRkNfaXJqZzZ3R3g4MmFUMWh6VnFHWUxFaXhTM1hQcUM3QWxZNzRnY1o4UXFCZGJPYks1TGx4Q2lJUUswa19jYk1YaUlodm9DU0RpVHQySllZVmNJV0J5eDhiU1MySXdSbFZfcVA0?oc=5","date":"2019-04-10","type":"pipeline","source":"The Pharma Letter","summary":"Kymab taps senior Merck KGaA exec for top job - The Pharma Letter","headline":"Kymab taps senior Merck KGaA exec for top job","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOVjJOaTVIc0NJS0gwRjJZeURoSVVGUmhTWHRyOG8xMFNneGxYazRCN2xaeWw4MlY0eFRPWjlEMkJHSWdHaW1QSUU5M3NWSzA5VGwwVTdrUk9ha0NMQm5tbWRETno2NGxFV3lPWWlvZ1lfTEhUVVZlTHVSaGlzYjEzMkZ4NW9YYmVKdjBJdw?oc=5","date":"2019-04-08","type":"pipeline","source":"fiercebiotech.com","summary":"U.K. biotech Kymab nabs new CEO from Merck KGaA - fiercebiotech.com","headline":"U.K. biotech Kymab nabs new CEO from Merck KGaA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPbFNtOVZIMlhKYjFHR2hwMkxld1k5R0hzZlY1UXFsbVVHeU5UUnRENE85YU8ySFBZWnJrdUVDbmVZNVRHcllWLUlvVm9QT2RrcTJtT2VaX1p2NG45SE9ZTDItMDBhU2l4Tlg3UDgtNVdIUC1iUXNBQVptU1dOQlhpU05iSkdZRnFYZkluQ3pB?oc=5","date":"2016-10-11","type":"deal","source":"pharmaphorum","summary":"Kymab signs immuno-oncology deal for bi-specific antibodies - pharmaphorum","headline":"Kymab signs immuno-oncology deal for bi-specific antibodies","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}